Online first
Artykuł przeglądowy
Opublikowany online: 2025-03-04
Wyświetlenia strony
106
Wyświetlenia/pobrania artykułu
12
Miejsce erdosteiny w terapii wspomagającej przewlekłej obturacyjnej choroby płuc
Streszczenie
Leki mukoaktywne wpływają na wytwarzanie i usuwanie śluzowej wydzieliny, a także wykazują działanie antyoksydacyjne
i przeciwzapalne. W terapii przewlekłej obturacyjnej choroby płuc leki te były zalecane jako leczenie wspomagające u pacjentów
niestosujących wziewnych glikokortykosteroidów. W 2023 r. wytyczne GOLD wskazały, że erdosteina może być stosowana
niezależnie od terapii glikokortykosteroidami, gdyż w randomizowanych badaniach wykazano, że lek ten pozwala na ograniczenie
liczby zaostrzeń, skrócenie czasu ich trwania oraz poprawę ogólnego stanu zdrowia chorych.
Decyzja o rozpoczęciu leczenia lekami mukoaktywnymi wymaga rozważenia szeregu czynników związanych z przebiegiem
i nasileniem choroby. W niniejszym przeglądzie podsumowano aktualne dane kliniczne oraz sformułowano zalecenia dotyczące
stosowania leków mukoaktywnych, w szczególności erdosteiny, w terapii przewlekłej obturacyjnych choroby płuc.
Słowa kluczowe: erdosteinaleki mukoaktywneprzewlekła obturacyjna choroba płucstres oksydacyjny
Referencje
- Global strategy for diagnosis, managment, and prevention of chronic obstructive pulmonary disease (2024 report). https://goldcopd.org/2024-gold-report/ (2024).
- Doniec Z, Jackowska T, Sybilski AJ, et al. Zastosowanie karbocysteiny w zakażeniach górnych i dolnych dróg oddechowych – stanowisko ekspertów. Lekarz POZ. 2024; 10(4): 305–11.
- Rahman I, MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J. 2000; 16(3): 534–554.
- Cantin AM, North SL, Hubbard RC, et al. Normal alveolar epithelial lining fluid contains high levels of glutathione. J Appl Physiol (1985). 1987; 63(1): 152–157.
- Nowak A, Pawliczak R. Cigarette smoking and oxidative stress. Alergologia Polska - Polish Journal of Allergology. 2022; 9(2): 89–98.
- Barnes PJ. Oxidative Stress in Chronic Obstructive Pulmonary Disease. Antioxidants (Basel). 2022; 11(5).
- Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences--clinical impact, mechanisms, and potential for early intervention. COPD. 2008; 5(4): 235–256.
- MacNee W. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Ann Med. 2013; 45(3): 291–300.
- Aydemir Y, Aydemir Ö, Şengül A, et al. Comparison of oxidant/antioxidant balance in COPD and non-COPD smokers. Heart Lung. 2019; 48(6): 566–569.
- Nucera F, Mumby S, Paudel KR, et al. Role of oxidative stress in the pathogenesis of COPD. Minerva Med. 2022; 113(3): 370–404.
- Drost EM, Skwarski KM, Sauleda J, et al. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax. 2005; 60(4): 293–300.
- Matera MG, Calzetta L, Cazzola M. Oxidation pathway and exacerbations in COPD: the role of NAC. Expert Rev Respir Med. 2016; 10(1): 89–97.
- Fischer BM, Voynow JA, Ghio AJ. COPD: balancing oxidants and antioxidants. Int J Chron Obstruct Pulmon Dis. 2015; 10: 261–276.
- Zatloukal J, Brat K, Neumannova K, et al. Chronic obstructive pulmonary disease - diagnosis and management of stable disease; a personalized approach to care, using the treatable traits concept based on clinical phenotypes. Position paper of the Czech Pneumological and Phthisiological Society. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020; 164(4): 325–356.
- Keuhkoahtaumatauti Internet: Finnish Medical Society Duodecim, Finnish Association of Pulmonologists. https://www.kaypahoito.fi/hoi06040#K1 (2020).
- Zysman M, Ribeiro Baptista B, Soumagne T, et al. [Pharmacological treatment optimisation in patients with stale COPD. Position of the French-language Respiratory Society. 2021 Update]. Rev Mal Respir. 2021; 38(5): 539–561.
- Miravitlles M, Calle M, Molina J, et al. Spanish COPD Guidelines (GesEPOC) 2021: Updated Pharmacological treatment of stable COPD. Arch Bronconeumol. 2022; 58(1): 69–81.
- Global Strategy for Diagnosis, Management, and Prevention of COPD (2017 Report). Global Initiative for Chronic Obstructive Lung Disease. ; 2017.
- Dal Negro RW, Wedzicha JA, Iversen M, et al. RESTORE group, RESTORE study. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur Respir J. 2017; 50(4).
- Calverley PMa, Page C, Dal Negro RW, et al. Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation. Int J Chron Obstruct Pulmon Dis. 2019; 14: 2733–2744.
- Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019; 5(5): CD001287.
- Murray AS. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease: A Cochrane review summary. Int J Nurs Stud. 2021; 124: 103711.
- Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017; 12(1): 103–111.
- Rogliani P, Matera MG, Page C, et al. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respir Res. 2019; 20(1): 104.
- Papadopoulou E, Hansel J, Lazar Z, et al. Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis. Eur Respir Rev. 2023; 32(167).
- Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005; 365(9470): 1552–1560.
- Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008; 371(9629): 2013–2018.
- Zheng JP, Wen FQ, Bai CX, et al. PANTHEON study group. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014; 2(3): 187–194.
- Papi A, Zheng J, Criner GJ, et al. Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study. Respir Med. 2019; 147: 37–43.
- Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015; 10: 2207–2217.
- Jochmann A, Neubauer F, Miedinger D, et al. General practitioner's adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study. Swiss Med Wkly. 2010; 140.
- Lucas AEM, Smeenk FW, Smeele IJ, et al. Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients, an exploratory study. Fam Pract. 2008; 25(2): 86–91.
- Al Wachami N, Guennouni M, Iderdar Y, et al. Estimating the global prevalence of chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMC Public Health. 2024; 24(1): 297.
- David B, Bafadhel M, Koenderman L, et al. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021; 76(2): 188–195.
- Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013; 131(3): 636–645.
- Barnes PJ. Inflammatory endotypes in COPD. Allergy. 2019; 74(7): 1249–1256.
- Lewis BW, Ford ML, Rogers LK, et al. Oxidative Stress Promotes Corticosteroid Insensitivity in Asthma and COPD. Antioxidants (Basel). 2021; 10(9).
- Calverley PMA, Papi A, Page C, et al. The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset. Int J Chron Obstruct Pulmon Dis. 2022; 17: 1909–1920.
- Braga PC, Dal Sasso M, Sala MT, et al. Effects of erdosteine and its metabolites on bacterial adhesiveness. Arzneimittelforschung. 1999; 49(4): 344–350.
- Braga PC, Zuccotti T, Dal Sasso M. Bacterial adhesiveness: effects of the SH metabolite of erdosteine (mucoactive drug) plus clarithromycin versus clarithromycin alone. Chemotherapy. 2001; 47(3): 208–214.
- Dal SM, Bovio C, Culici M, et al. The combination of the SH metabolite of erdosteine (a mucoactive drug) and ciprofloxacin increases the inhibition of bacterial adhesiveness achieved by ciprofloxacin alone. Drugs Exp Clin Res. 2002;28(2-3. : 75–82.
- Moretti M, Bottrighi P, Dallari R, et al. EQUALIFE Study Group. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res. 2004; 30(4): 143–152.
- Welte T, Vogelmeier C, Papi A. COPD: early diagnosis and treatment to slow disease progression. Int J Clin Pract. 2015; 69(3): 336–349.
- Papi A, Avdeev S, Calverley PMA, et al. Use of mucolytics in COPD: A Delphi consensus study. Respir Med. 2020; 175: 106190.
- Crisafulli E, Coletti O, Costi S, et al. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study. Clin Ther. 2007; 29(9): 2001–2009.
- Yipin T, editor; Curative effect analysis of treating senile bronchiectasis and mucus hypersecretion by Erdosteine 2012.
- Buquan Z, Xinke L. Curative Effect of Treating Elderly Bronchiectasis and Mucus Hypersecretion Patients. The Journal of Practical Medicine. 2011; 27(6).
